Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples

American Journal of Surgical Pathology

Volumn 34, Issue 12, 2010, Pages 1805-1811

  Terry, Jefferson ^a   Leung, Samuel ^a   Laskin, Janessa ^a   Leslie, Kevin O ^b   Gown, Allen M ^c   Ionescu, Diana N ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b MAYO CLINIC   (United States)

^c PHENOPATH LABORATORIES   (United States)

Author keywords

adenocarcinoma; biopsy; immunohistochemistry; non small cell lung carcinoma; squamous cell carcinoma

Indexed keywords

TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ALGORITHM; ARTICLE; BIOPSY; DIFFERENTIAL DIAGNOSIS; ENZYME IMMUNOASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; SQUAMOUS CELL CARCINOMA; STATISTICAL MODEL; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BIOPSY; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650384780     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181f7dae3     Document Type: Article

References (35)

1. American Cancer Society. Cancer Facts and Figures 2010. Atlanta: American Cancer Society 2009, 2-8.
2. Au NH, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immuno-histochem Mol Morphol. 2004;12:240-247.
3. Bishop JA, Benjamin H, Cholakh H, et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res. 2010;16:610-619.
4. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41:20-25.
5. Camilo R, Capelozzi VL, Siqueira SA, et al. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol. 2006;37:542-546.
6. Canadian Cancer Society. Canadian Cancer Society's Steering Committee: Canadian Cancer Statistics 2010. Toronto: Canadian Cancer Society; 2010:11-15.
7. Cataluna JJ, Perpina M, Greses JV, et al. Cell type accuracy of bronchial biopsy specimens in primary lung cancer. Chest. 1996;109:1199-1203.
8. Chuang MT, Marchevsky A, Teirstein AS, et al. Diagnosis of lung cancer by fibreoptic bronchoscopy: problems in the histological classification of non-small cell carcinomas. Thorax. 1984;39:175-178.
9. Colby T, Noguchi M, Henschke C, et al. Tumors of the lung. In: Travis WD, Barambilla E, Muller Hermelink HK, et al, eds. WHO Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004:9-122.
10. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11:3766-3772.
11. Downey P, Cummins R, Moran M, et al. If it's not CK5/6 positive, TTF-1 negative it's not a squamous cell carcinoma of lung. APMIS. 2008;116:526-529.
12. Edwards SL, Roberts C, McKean ME, et al. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol. 2000;53:537-540.
13. Fukuoka J, Dracheva T, Shih JH, et al. Desmoglein 3 as a prognostic factor in lung cancer. Hum Pathol. 2007;38:276-283.
14. Grilley-Olson JE, Hayes DN, Qaqish BF, et al. Diagnostic reproducibility of squamous cell carcinoma (SC) in the era of histology-directed non-small cell lung cancer (NSCLC) chemotherapy: a large prospective study. J Clin Oncol. 2009;27:a8008.
15. Hirano T, Gong Y, Yoshida K, et al. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer. 2003;41:155-162.
16. Hirsch FR, Spreafico A, Novello S, et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol. 2008;3:1468-1481.
17. Ionescu DN, Treaba D, Gilks CB, et al. Nonsmall cell lung carcinoma with neuroendocrine differentiation-an entity of no clinical or prognostic significance. Am J Surg Pathol. 2007;31:26-32.
18. Jorda M, Gomez-Fernandez C, Garcia M, et al. P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples: implications in treatment selection. Cancer Cytopathol. 2009;117:46-50.
19. Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol. 2007;15:415-420.
20. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarci-nomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000;36:8-16.
21. Khayyata S, Yun S, Pasha T, et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol. 2009;37: 178-183.
22. Li Q, Bavikatty N, Michael CW. The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adeno-carcinoma in pleural effusion. Semin Diagn Pathol. 2006;23:15-19.
23. Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undiffer-entiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol. 2010;5:442-447.
24. Monica V, Ceppi P, Righi L, et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol. 2009;22:709-717.
25. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol. 2010;5:436-441.
26. Ou SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol. 2009;4:1202-1211.
27. Pardo J, Martinez-Penuela AM, Sola JJ, et al. Large cell carcinoma of the lung: an endangered species? Appl Immunohistochem Mol Morphol. 2009;17:382-392.
28. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330-353.
29. Pu RT, Pang Y, Michael CW. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol. 2008;36: 20-25.
30. Ring BZ, Seitz RS, Beck RA, et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol. 2009;22:1032-1043.
31. Savci-Heijink CD, Kosari F, Aubry MC, et al. The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung. Am J Pathol. 2009;174:1629-1637.
32. Suzuki A, Shijubo N, Yamada G, et al. Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol Res Pract. 2005;201:579-586.
33. Terry J, De Luca A, Leung S, et al. Immunohistochemical expression of neurotrophic tyrosine kinase receptors 1 and 2 in lung carcinoma: potential discriminators between squamous and non-squamous subtypes. Arch Pathol Lab Med. 2010. (In press)
34. Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol. 2010;5:411-414.
35. Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer. 2003;88:1229-1233.